JP2008539745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539745A5 JP2008539745A5 JP2008510513A JP2008510513A JP2008539745A5 JP 2008539745 A5 JP2008539745 A5 JP 2008539745A5 JP 2008510513 A JP2008510513 A JP 2008510513A JP 2008510513 A JP2008510513 A JP 2008510513A JP 2008539745 A5 JP2008539745 A5 JP 2008539745A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- polypeptide
- disease
- helix
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000040430 polynucleotide Human genes 0.000 claims 40
- 108091033319 polynucleotide Proteins 0.000 claims 40
- 239000002157 polynucleotide Substances 0.000 claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 102000003951 Erythropoietin Human genes 0.000 claims 10
- 108090000394 Erythropoietin Proteins 0.000 claims 10
- 229940105423 erythropoietin Drugs 0.000 claims 10
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000001120 cytoprotective effect Effects 0.000 claims 7
- 230000003394 haemopoietic effect Effects 0.000 claims 7
- 230000000324 neuroprotective effect Effects 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 3
- 206010033892 Paraplegia Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000000750 progressive effect Effects 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 244000105975 Antidesma platyphyllum Species 0.000 claims 1
- 241000239290 Araneae Species 0.000 claims 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 claims 1
- 102000007371 Ataxin-3 Human genes 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006542 Bulbar palsy Diseases 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 206010052369 Encephalitis lethargica Diseases 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 102000019203 Follistatin-Related Proteins Human genes 0.000 claims 1
- 108010012820 Follistatin-Related Proteins Proteins 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 241000699694 Gerbillinae Species 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000016222 Pancreatic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 208000021811 Sandhoff disease Diseases 0.000 claims 1
- 208000032930 Spastic paraplegia Diseases 0.000 claims 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 208000025434 cerebellar degeneration Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 230000006726 chronic neurodegeneration Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003073 embolic effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 230000035558 fertility Effects 0.000 claims 1
- 235000009424 haa Nutrition 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- -1 helix A Chemical compound 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000001282 primary progressive aphasia Diseases 0.000 claims 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims 1
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 1
- 201000000196 pseudobulbar palsy Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 210000003523 substantia nigra Anatomy 0.000 claims 1
- 230000019635 sulfation Effects 0.000 claims 1
- 238000005670 sulfation reaction Methods 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05010473A EP1736481A1 (en) | 2005-05-13 | 2005-05-13 | Erythropoietin variants |
| EP05010473.6 | 2005-05-13 | ||
| PCT/EP2006/004564 WO2006120030A1 (en) | 2005-05-13 | 2006-05-15 | Erythropoietin variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008539745A JP2008539745A (ja) | 2008-11-20 |
| JP2008539745A5 true JP2008539745A5 (OSRAM) | 2009-07-02 |
| JP5231214B2 JP5231214B2 (ja) | 2013-07-10 |
Family
ID=36753959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510513A Active JP5231214B2 (ja) | 2005-05-13 | 2006-05-15 | エリスロポエチン変異体 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1736481A1 (OSRAM) |
| JP (1) | JP5231214B2 (OSRAM) |
| KR (1) | KR101468737B1 (OSRAM) |
| CN (1) | CN101175768B (OSRAM) |
| AU (1) | AU2006245916B2 (OSRAM) |
| BR (1) | BRPI0608769A2 (OSRAM) |
| CA (1) | CA2608379C (OSRAM) |
| DK (1) | DK1885747T3 (OSRAM) |
| ES (1) | ES2457398T3 (OSRAM) |
| RU (1) | RU2430162C2 (OSRAM) |
| WO (1) | WO2006120030A1 (OSRAM) |
| ZA (1) | ZA200709091B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2540309T3 (pl) | 2005-08-05 | 2018-03-30 | Araim Pharmaceuticals, Inc. | Peptydy chroniące tkanki i ich zastosowanie |
| US20100267576A1 (en) * | 2007-05-02 | 2010-10-21 | University Of Utah Research Foundation | Compositions And Methods For Identifying And Treating Subjects At Risk Of Developing Type 2 Diabetes |
| DE102007031708A1 (de) * | 2007-07-06 | 2009-01-08 | Dade Behring Marburg Gmbh | Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin |
| JP5542064B2 (ja) | 2008-01-22 | 2014-07-09 | アライム ファーマシューティカルズ，インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体 |
| BR112014007029A2 (pt) | 2011-09-23 | 2017-04-11 | Bluebird Bio Inc | métodos aperfeiçoados de terapia gênica |
| KR101148191B1 (ko) * | 2011-09-27 | 2012-05-23 | 김후정 | 에리스로포이에틴-유래 펩타이드 및 그 용도 |
| EP3851454A1 (en) | 2012-12-05 | 2021-07-21 | Novartis AG | Compositions and methods for antibodies targeting epo |
| EP2953473B1 (en) | 2013-02-06 | 2018-11-28 | Nc Medical Research Inc. | Method of producing a heterogeneous subpopulation of bone marrow cells suitable for the treatement of neurodegeneration cased by ischemic stroke |
| ES2913530T3 (es) | 2015-08-12 | 2022-06-02 | Novartis Ag | Métodos para tratar trastornos oftálmicos |
| CN108137664B (zh) * | 2015-08-31 | 2021-11-26 | 宾夕法尼亚州大学信托人 | 用于治疗伴侣动物的aav-epo |
| EP3587443A4 (en) * | 2017-02-27 | 2021-02-17 | Sylus Co., Ltd. | USE OF ERYTHROPOIETIN PEPTIDE BY EFFECT ON CELL DAMAGE PREVENTION THEREOF |
| CN107880109B (zh) * | 2017-11-01 | 2019-08-30 | 复旦大学附属中山医院 | 一种促红细胞生成素来源肽及其制备方法和用途 |
| AR113091A1 (es) * | 2018-09-27 | 2020-01-22 | Univ Nacional Del Litoral | Eritropoyetina humana modificada |
| EP3916008A1 (en) * | 2020-05-26 | 2021-12-01 | Sylus Co., Ltd. | New peptide and use thereof for treatment of disease of brain and nervous system |
| CN113376186B (zh) * | 2021-05-12 | 2022-12-23 | 无锡科金生物科技有限公司 | 一种精准度高的智能红细胞叶酸检测仪及其检测方法 |
| IL309264A (en) * | 2021-06-15 | 2024-02-01 | Andremacon S R L | EPO variants and modulators |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4558006A (en) * | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| US6271196B1 (en) * | 1996-03-05 | 2001-08-07 | Regents Of The University Of Ca | Methods of alleviating neuropathic pain using prosaposin-derived peptides |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| US7259146B2 (en) | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
| DE10043457A1 (de) | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| EP1552298A4 (en) * | 2002-07-01 | 2006-11-08 | Kenneth S Warren Inst Inc | RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF |
| US20040091961A1 (en) * | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
| BRPI0409650A (pt) | 2003-09-09 | 2006-04-25 | Warren Pharmaceuticals Inc | métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica |
| CA2563874A1 (en) * | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Erythropoietin protein variants |
-
2005
- 2005-05-13 EP EP05010473A patent/EP1736481A1/en not_active Withdrawn
-
2006
- 2006-05-15 CN CN2006800165436A patent/CN101175768B/zh not_active Expired - Fee Related
- 2006-05-15 AU AU2006245916A patent/AU2006245916B2/en not_active Ceased
- 2006-05-15 ES ES06753630.0T patent/ES2457398T3/es active Active
- 2006-05-15 RU RU2007146455/10A patent/RU2430162C2/ru not_active IP Right Cessation
- 2006-05-15 CA CA2608379A patent/CA2608379C/en not_active Expired - Fee Related
- 2006-05-15 EP EP06753630.0A patent/EP1885747B1/en active Active
- 2006-05-15 JP JP2008510513A patent/JP5231214B2/ja active Active
- 2006-05-15 WO PCT/EP2006/004564 patent/WO2006120030A1/en not_active Ceased
- 2006-05-15 DK DK06753630.0T patent/DK1885747T3/en active
- 2006-05-15 BR BRPI0608769-8A patent/BRPI0608769A2/pt not_active IP Right Cessation
-
2007
- 2007-10-22 ZA ZA200709091A patent/ZA200709091B/xx unknown
- 2007-11-12 KR KR1020077026286A patent/KR101468737B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008539745A5 (OSRAM) | ||
| JP6784724B2 (ja) | 改善された二重特異性ポリペプチド分子 | |
| JP4642943B2 (ja) | 小脳由来成長因子、及びそれに関連する利用 | |
| JP2012529272A5 (OSRAM) | ||
| Kovesdi et al. | Heparin-binding neurotrophic factor (HBNF) and MK, members of a new family of homologous, developmentally regulated proteins | |
| JP2020500015A5 (OSRAM) | ||
| RU2007146455A (ru) | Варианты эритропоэтина | |
| JP2020506701A (ja) | 組織特異的Ｗｎｔシグナル増強分子およびその使用 | |
| SK25296A3 (en) | Protocadherin proteins and their uses | |
| JPH06500466A (ja) | Ｇｄｆ―１ | |
| JPH10502527A (ja) | ＴＧＦ−βファミリーの新規な成長／分化因子 | |
| JP2016523919A5 (OSRAM) | ||
| CA2020729A1 (en) | Bone morphogenetic protein | |
| JP2002518010A5 (OSRAM) | ||
| KR20100129341A (ko) | 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제 | |
| JP2002506625A5 (OSRAM) | ||
| CA2323776A1 (en) | Cytokine receptor common gamma chain like | |
| JP2002511762A (ja) | ネズミおよびヒトのサーベラス様蛋白およびそれらを含有する組成物 | |
| WO2007010989A1 (ja) | 神経分化誘導ペプチド及びその利用 | |
| JP3921271B2 (ja) | グルクロン酸転移酵素をコードするｄｎａ | |
| JPH10147597A (ja) | 可溶性ポリペプチド | |
| JPS60221093A (ja) | Ｄｎａ配列 | |
| JPWO2021191447A5 (OSRAM) | ||
| US9315561B2 (en) | Compositions comprising the NC2 domain of collagen IX and methods of using same | |
| Li et al. | Expression, characterization, and preliminary X-ray crystallographic analysis of recombinant murine Follistatin-like 1 expressed in Drosophila S2 cells |